PharmaGossip (Free subscription) | 10/30/2009
Back story. AstraZeneca is looking into whether greater use of aspirin reduces the effectiveness of its experimental clot-busting medicine Brilinta, which analysts had estimated would bring in $1 billion a year. AstraZeneca’s Brilinta beat Sanofi-Aventis SA and Bristol- Myers Squibb Co.’s blood thinner Plavix in a study, preventing 16 percent more heart attacks, strokes and deaths. The...
Health - The Post Chronicle (Free subscription) | 09/29/2009
The chief executive officer of Sanofi-Aventis SA said on Tuesday his company has begun U.S. shipments of its H1N1 swine flu vaccine ahead of schedule....
The Reaction (Free subscription) | 09/24/2009
By Carl It's taken thirty years, countless dead and infected, and a worldwide push, but it looks as though the very tricky and difficult HIV virus may be giving up its secrets to science : Sept. 24 (Bloomberg) -- An experimental vaccine prevented HIV infections for the first time, a breakthrough that has eluded scientists for a quarter century. A U.S.-funded study involving more than 16,000 volunteers...
Randy McDonald's Livejournal (Free subscription) | 09/24/2009
Most of you have probably heard the very encouraging news about the development of what might be the first partially successful HIV vaccine . A U.S.-funded study involving more than 16,000 volunteers in Thailand found that a combination of ALVAC, made by Paris- based Sanofi-Aventis SA, and AIDSVAX, from VaxGen Inc., of South San Francisco, cut infections by 31.2 percent in the people who received it...
Simply Left Behind (Free subscription) | 09/24/2009
It's taken thirty years, countless dead and infected, and a worldwide push, but it looks as though the very tricky and difficult HIV virus may be giving up its secrets to science : Sept. 24 (Bloomberg) -- An experimental vaccine prevented HIV infections for the first time, a breakthrough that has eluded scientists for a quarter century. A U.S.-funded study involving more than 16,000 volunteers in Thailand...
Business Wire (Free subscription) | 09/22/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lennar Corporation (LEN), VeriChip (CHIP), Sanofi-Aventis SA (SFY), AstraZeneca (AZN) and Novartis AG (NOV). Get the most recent insight...
Click here to see all comments
MAXIDEX DEXAMTHASONE WARNING
I had eye surgery and in the post-op pack was MXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...
SeekingAlpha.com (Free subscription) | 09/21/2009
Zacks.com submits: An announcement today regarding the exclusive license granted to controversial chip-implant maker VeriChip ( CHIP ) for H1N1 detection sent CHIP shares hurtling nearly out of orbit -- up 178%, or over $2 per share -- to around $3.20 by Monday afternoon. Other news reports have cited that this is the biggest intra-day gain since the company went public in February 2007. VeriChip's...
Physorg (Free subscription) | 09/21/2009
(AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.
Tampa Bay Online (Free subscription) | 09/21/2009
PARIS - Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.
Arizona Republic (Free subscription) | 09/21/2009
PARIS (AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday....
Daily Advance - Business (Free subscription) | 09/21/2009
PARIS — Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine i...
Examiner (Free subscription) | 09/21/2009
Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.
kansascity.com (Free subscription) | 09/21/2009
Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.
San Fransisco Chronicle (Free subscription) | 09/21/2009
Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday. In an interview with French daily Le Figaro, Chris Viehbacher said... Sponsored Topics: United States - France - Swine influenza - Sanofi-Aventis - Health
Seattle Times (Free subscription) | 09/21/2009
Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.
The last article published by a user on Sanofi-Aventis SA :
hearttoheartafrica.org | 11/11/2008
Under development by Sanofi-Aventis , Acomplia ( rimonabant ) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In USA, Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients
Videos